The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.
Sandoz has announced that the US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for the treatment of various conditions.
Some of these conditions include osteoporosis in postmenopausal women and in men at increased risk of fractures, prevention of skeletal-related complications in cancer that has spread to the bone, treatment-induced bone loss, giant cell tumor of the bone, and treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy, according to a company press release.
Denosumab is a human monoclonal antibody, created to bind to the RANKL protein, which is an activator of osteoclasts. The medicine decreases the activity of osteoclasts by inhibiting the RANKL protein, leading to a decrease in bone loss and the probability of fractures and other bone conditions, per Sandoz.
“In addition to being an important medicine for cancer of the bone, denosumab is critical in the treatment of osteoporosis and potential prevention of osteoporosis-related fractures that so many women over 50 are at risk of,” said Keren Haruvi, president of Sandoz Inc. and head of North America.
She added, “We are proud to be among the first to submit a BLA for a denosumab biosimilar as, if approved, it could increase patient access to an affordable, high-quality, potentially disease-modifying treatment across the US, while also delivering savings for healthcare systems.”
The BLA acceptance was based on positive clinical data from the ROSALIA study. Results from the study confirm the proposed biosimilar denosumab matches the reference medication in efficacy, safety immunogenicity, pharmacokinetics, and pharmacodynamics in women with postmenopausal osteoporosis.
Reference
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA. Novartis. February 6, 2023. Accessed February 6, 2023. https://www.novartis.com/news/media-releases/sandoz-biologics-license-application-proposed-biosimilar-denosumab-accepted-us-fda
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More